Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kitasato Daiichi Sankyo Vaccine, the domestic subsidiary of Daiichi Sankyo Company, is seeking approval for the cell culture-based pandemic influenza vaccine in Japan.
Subscribe to our email newsletter
The company has submitted a new drug application for the vaccine to the Ministry of Health, Labour and Welfare in Japan.
In August 2011, the Ministry of Health, Labour and Welfare in Japan offered a grant to Kitasato Daiichi Sankyo Vaccine for a cell culture vaccine production facility and vaccine development.
Supported by the grant, Kitasato Daiichi has been working to build up production capacity by the end of March 2014.
Commonly known as the flu, Influenza is an infectious disease of birds and mammals caused by RNA viruses of the family Orthomyxoviridae, the influenza viruses.